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Modern biotechnology research may help reduce poverty,
improve food security and nutrition, and make the use of
natural resources more sustainable, only if it focuses on the
problems and opportunities poor people in developing
countries face and only if appropriate policies accompany it.
Modern biotechnology can enhance agricultural productivity in developingcountries in a way that further reduces poverty, improves food security andnutrition, and promotes sustainable use of natural resources. But such bene-
fits from biotechnology require policy action on a number of fronts. The small
farmer in developing countries faces a variety of problems and constraints. Crop
losses due to insects, diseases, weeds, and drought threaten income and food avail-
ability. Acid soils, low soil fertility and lack of access to reasonably priced plant nutri-
ents, and other biotic and abiotic factors also contribute to low yields. Poor
infrastructure and dysfunctional markets for inputs and outputs, along with lack of
access to credit and technical assistance, add to the problems plaguing the small
farmer. Solutions to these problems will benefit both farmers and consumers.
Although modern biotechnology cannot solve all these problems, it can provide a
critical component to the solution if it is guided by appropriate policies. Four sets
of policies are particularly important. Each of these is briefly discussed below.
Policies to Guide Research for the Poor
Policies must expand and guide research and technology development to solve the
problems of particular importance to the poor. These problems include diets with
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inadequate levels of energy, protein, and micronutrients, and crop losses due to biot-
ic and abiotic factors. Research should focus on the crops of particular importance
to small farmers and poor consumers in developing countries. Bananas, cassava,
yams, sweet potatoes, rice, maize, wheat, and millet, along with livestock products,
feature most prominently in the diets and production activities of the poor. Except
for limited work on rice, bananas, and cassava, little biotechnology research currently
focuses on helping the small farmer and poor consumer solve their productivity and
nutrition problems. The prediction so often heard that the poor in developing coun-
tries are unlikely to benefit from modern agricultural biotechnology in the foresee-
able future could well come true—not because the technology has little to offer but
because it will not be given a chance.
Allocate Additional Public Resources to Agricultural Research
There are three ways to expand biotechnology research for the benefit of the poor.
First, allocate additional public resources to agricultural research, including biotech-
nology research, that promises large social benefits. Existing national and inter-
national agricultural research systems have to be strengthened or new ones built.
Low-income developing countries currently invest less than 0.5 percent of the value
of agricultural production in agricultural research, compared to about 2 percent in
developed countries. Underinvestment is widespread despite high annual economic
rates of return from investments in agricultural research. A recent assessment of more
than 1,000 research projects and programs found an average annual rate of return
of 88 percent. Investments by the private sector are limited to research that permits
a large enough profit from the returns. Nonetheless, privately funded research can
still generate large benefits to farmers and consumers, as illustrated by a recent study
of the distribution of benefits from the use of genetically modified (GM) soybeans
in the United States. The private patent holders and private seed companies cap-
tured one-third of the total economic benefits, farmers and consumers gained two-
thirds. While private-sector agricultural research has increased rapidly in the
industrialized countries during the last 10 to 15 years, it currently accounts for a
small share of agricultural research in most developing countries.
Convert Some Social Benefits to Private Benefits
Second, expand private-sector research for the poor by converting some of the
social benefits of research to private benefits for the private sector. The public sec-
tor can entice the private sector to develop technologies for the poor by offering up
front to buy the exclusive rights to newly developed technology and make it avail-
able either for free or for a nominal charge to small farmers. The amount of the offer
could be determined on the basis of expected social benefits, using an annual rate
of return normally expected from agricultural research, for example, 60–80 percent.
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The risk of failing to develop the specified technology would rest with the research
agency, just as it does when technology is developed for the market. The public sec-
tor offer would come due to the research agency that first develops the technology,
but only when the technology is developed, tested, and made available. Both pri-
vate- and public-sector agencies could participate in this research. Opportunities for
collaboration between multinational life science companies and public-sector agri-
cultural research agencies in both developing and developed countries might increase
the probability of success. With necessary refinements, the arrangement proposed
here should be of interest to international development assistance agencies. This pro-
posal builds on a similar idea that Jeffrey Sachs of Harvard University proposed for
developing vaccines for tropical diseases.
Protect Intellectual Property Rights
The third way to expand biotechnology research to help the poor is to protect the intel-
lectual property rights of a private research agency that develops a particular technol-
ogy, for example, seed with infertile offspring, or that contracts directly with the
farmer, in both cases forcing the farmer to buy new seed every season. This would make
it easier for the private sector to recuperate the incomes needed to justify the research.
But seeds with infertile offspring may be inappropriate for small farmers in develop-
ing countries because they pose large risks to food security. Existing infrastructure and
production processes may not be able to keep fertile and infertile seeds apart. Small
farmers could face severe consequences if they planted infertile seeds by mistake.
Monitoring and enforcing contracts that prohibit large numbers of small farmers from
using the crops they produce as seed would be expensive and difficult to do.
Policies to Protect against Health Risks
GM foods are not intrinsically good or bad for human health. Their health effect
depends on their specific content. GM foods with a higher content of digestible iron
are likely to benefit consumers with iron deficiencies. But the transfer of genes from
one species to another may also transfer characteristics that cause allergic reactions.
Thus, GM foods need to be tested for allergy transfers before they are commer-
cialized. It was precisely such testing that avoided the commercialization of maize
with a Brazil nut gene. GM foods with possible allergy risks should be fully labeled.
Labeling may also be needed to identify content for cultural and religious reasons
or simply because consumers want to know. Finally, labeling may be required to
identify the production process itself when that, rather than any specific health risk,
interests consumers.
Failure to remove antibiotic-resistant marker genes used in research before a
GM food is commercialized presents a potential although unproven health risk.
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Recent legislation in the European Union requires that such marker genes be
removed before a GM food is deemed safe for consumers. Risks and opportunities
associated with GM foods should be integrated into the general food safety regula-
tions of a country.
Policies to Address Ecological Risks
Effective national biosafety regulations should be in place before modern biotech-
nology is introduced into a country’s agriculture. Such regulations should be coun-
try-specific and reflect relevant risk factors. The ecological risks policymakers need
to assess include the spread of traits such as herbicide resistance from genetically
modified plants to plants (including weeds) that are not modified, and the build-
up of resistance in insect populations. Seeds that produce infertile offspring may be
an effective solution to the risk associated with cross pollination but, as mentioned
earlier, they may be inappropriate for small farmers. The approach used to develop
terminator seeds, however, offers great promise for the development of a seed that
will avoid the spread of new traits through cross-pollination. The seed would
contain the desired traits, such as pest resistance or drought tolerance, but each trait
would be activated only after treatment with a particular chemical. Without treat-
ment, the seed would maintain its normal characteristics. Thus, if a farmer planted
an improved seed, the offspring would not be sterile; rather they would revert back
to being normal seeds (before improved traits were introduced). The farmer would
then have the choice of planting the normal seed or bringing back the improved
traits by applying a particular chemical. Contrary to the terminator gene, this
approach complies with the principle of doing no harm.
Both food safety and biosafety regulations should reflect international agree-
ments and a society’s acceptable risk levels, including the risks associated with not
using modern biotechnology to achieve desired goals. The poor should be includ-
ed directly in the debate and decisionmaking about their desire for technological
change, the risks of that change, and the consequences of no or alternative kinds
of change.
Policies to Regulate the Private Sector
Recent mergers and acquisitions have resulted in increasing concentration among
companies engaged in biotechnology research. The outcome of this growing con-
centration may be reduced competition, monopoly or oligopoly profits, exploita-
tion of small farmers and consumers, and successful efforts to gain special favors
from governments. Effective antitrust legislation and institutions to enforce the leg-
islation are needed, particularly in small developing countries where one or only a
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few seed distribution companies operate. Effective legislation is also required to
enforce intellectual property rights, including those of farmers to germplasm, along
the lines agreed to within the frameworks of the World Trade Organization and the
Convention on Biological Diversity.
Conclusions
Modern biotechnology research may help reduce poverty, improve food security and
nutrition, and make the use of natural resources more sustainable, only if it focus-
es on the problems and opportunities poor people in developing countries face and
only if appropriate policies accompany it. Modern biotechnology is not a silver bul-
let, but it may be a powerful tool in the fight against poverty and should be made
available to poor farmers and consumers.
